Home › Compare › AALBF vs ABBV
AALBF yields 3.48% · ABBV yields 3.06%● Live data
📍 AALBF pulled ahead of the other in Year 8
Combined, AALBF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AALBF + ABBV for your $10,000?
Aalberts N.V. engineers mission-critical technologies. The company operates in two segments: Building Technology and Industrial Technology. The Building Technology segment develops, manufactures, and monitors hydronic flow control systems for heating and cooling to enhance the energy efficiency; and develops, designs, and manufactures integrated piping systems to distribute and regulate water or gas flows in heating, cooling, water, gas, and sprinkler systems in eco-friendly buildings and industrial niches. The Industrial Technology segment co-develops, engineers, and manufactures advanced mechatronics and technologies to regulate, measure, and control fluids under severe and critical conditions for active OEMs in semicon efficiency, sustainable transportation, and industrial niches; and offers a range of surface technologies utilizing a network of service locations local knowledge to customers active in sustainable transportation and industrial niches. It operates in Western Europe, the United States, Russia, Eastern Europe, the Asia-Pacific, the Middle East, and Africa. The company was formerly known as Aalberts Industries N.V. and changed its name to Aalberts N.V. in April 2019. Aalberts N.V. was founded in 1975 and is headquartered in Utrecht, the Netherlands.
Full AALBF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.